Matthew Karr, DO, highlights advances in the CLL paradigm, current goals in researching CNS lymphoma, and other future directions in hematology/oncology.
After an FDA Type C meeting, registrational trials of the DLL3-targeting ADC IDE849 in pretreated neuroendocrine carcinomas are set to begin by year-end.
At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.
The FDA granted breakthrough therapy designation to 64Cu-SAR-bisPSMA for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer.